Appointment of Joint Corporate Broker

AI SummaryClose X

Sareum Holdings PLC announced the appointment of Singer Capital Markets as Joint Corporate Broker, effective immediately. Strand Hanson Limited will remain the company's Nominated Adviser. Oberon Capital will also continue its role as Joint Corporate Broker. The company is a clinical-stage biotechnology company focused on developing next-generation kinase inhibitors for autoimmune disease and cancer. Sareum's lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1 and is a potential treatment for autoimmune diseases.

Disclaimer*

UK 100

Latest directors dealings